As of the latest Form 4 filed Jul 1, 2026.
What Oruka Therapeutics, Inc. insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 37 most recent filings for ORKA.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-07-01 | 2026-07-01 | Fairmount Funds Management LLC Director | SSale | −3.55M | $84.43 | $300M | No | Form 4 ↗ |
| 2026-07-01 | 2026-07-01 | Fairmount Funds Management LLC, Director | CConvert | +3.55M | — | — | No | Form 4 ↗ |
| 2026-07-01 | 2026-07-01 | Sandler Laura Lee Chief Operating Officer | SSale | −500.00 | $95.47 | $47.7K | Yes (planned) | Form 4 ↗ |
| 2026-07-01 | 2026-07-01 | Sandler Laura Lee, Chief Operating Officer | SSale | −2.26K | $94.75 | $214K | Yes (planned) | Form 4 ↗ |
| 2026-07-01 | 2026-07-01 | Sandler Laura Lee, Chief Operating Officer | SSale | −2.24K | $93.85 | $210K | Yes (planned) | Form 4 ↗ |
| 2026-07-01 | 2026-07-01 | Sandler Laura Lee, Chief Operating Officer | MExercise | +5.00K | $7.80 | $39.0K | Yes (planned) | Form 4 ↗ |
| 2026-06-22 | 2026-06-22 | Agarwal Arjun Senior Vice President, Finance | SSale | −699.00 | $82.15 | $57.4K | Yes (planned) | Form 4 ↗ |
| 2026-06-22 | 2026-06-22 | Agarwal Arjun, Senior Vice President, Finance | SSale | −888.00 | $80.01 | $71.0K | Yes (planned) | Form 4 ↗ |
| 2026-06-15 | 2026-06-15 | Agarwal Arjun Senior Vice President, Finance | SSale | −395.00 | $69.69 | $27.5K | Yes (planned) | Form 4 ↗ |
| 2026-06-15 | 2026-06-15 | Goncalves Joana Chief Medical Officer | SSale | −947.00 | $69.69 | $66.0K | Yes (planned) | Form 4 ↗ |
| 2026-06-15 | 2026-06-15 | Goncalves Joana, Chief Medical Officer | SSale | −300.00 | $70.62 | $21.2K | Yes (planned) | Form 4 ↗ |
| 2026-06-15 | 2026-06-15 | Goncalves Joana, Chief Medical Officer | SSale | −5.06K | $69.42 | $352K | Yes (planned) | Form 4 ↗ |
| 2026-06-15 | 2026-06-15 | Goncalves Joana, Chief Medical Officer | SSale | −1.64K | $68.38 | $112K | Yes (planned) | Form 4 ↗ |
| 2026-06-15 | 2026-06-15 | Goncalves Joana, Chief Medical Officer | MExercise | +3.50K | $7.80 | $27.3K | Yes (planned) | Form 4 ↗ |
| 2026-06-15 | 2026-06-15 | Goncalves Joana, Chief Medical Officer | MExercise | +3.50K | $6.84 | $23.9K | Yes (planned) | Form 4 ↗ |
| 2026-06-15 | 2026-06-15 | Klein Lawrence Otto Chief Executive Officer | SSale | −1.73K | $69.69 | $120K | No | Form 4 ↗ |
| 2026-06-15 | 2026-06-15 | Sandler Laura Lee Chief Operating Officer | SSale | −600.00 | $69.69 | $41.8K | No | Form 4 ↗ |
| 2026-06-15 | 2026-06-15 | Quinlan Paul T General Counsel | SSale | −733.00 | $69.69 | $51.1K | No | Form 4 ↗ |
| 2026-06-15 | 2026-06-12 | Agarwal Arjun Senior Vice President, Finance | SSale | −3.26K | $70.34 | $229K | Yes (planned) | Form 4 ↗ |
| 2026-06-15 | 2026-06-12 | Agarwal Arjun, Senior Vice President, Finance | SSale | −4.34K | $69.85 | $303K | Yes (planned) | Form 4 ↗ |
| 2026-06-15 | 2026-06-12 | Agarwal Arjun, Senior Vice President, Finance | SSale | −1.86K | $68.34 | $127K | Yes (planned) | Form 4 ↗ |
| 2026-06-15 | 2026-06-12 | Agarwal Arjun, Senior Vice President, Finance | MExercise | +1.46K | $34.39 | $50.2K | Yes (planned) | Form 4 ↗ |
| 2026-06-15 | 2026-06-12 | Agarwal Arjun, Senior Vice President, Finance | MExercise | +8.00K | $12.50 | $100K | Yes (planned) | Form 4 ↗ |
| 2026-06-12 | 2026-06-12 | Dambkowski Carl Director | SSale | −12.6K | $70.11 | $882K | Yes (planned) | Form 4 ↗ |
| 2026-06-12 | 2026-06-11 | Dambkowski Carl, Director | SSale | −22.4K | $70.13 | $1.57M | Yes (planned) | Form 4 ↗ |
| 2026-05-01 | 2026-05-01 | Sandler Laura Lee Chief Operating Officer | SSale | −100.00 | $68.48 | $6.85K | Yes (planned) | Form 4 ↗ |
| 2026-05-01 | 2026-05-01 | Sandler Laura Lee, Chief Operating Officer | SSale | −200.00 | $67.16 | $13.4K | Yes (planned) | Form 4 ↗ |
| 2026-05-01 | 2026-05-01 | Sandler Laura Lee, Chief Operating Officer | SSale | −400.00 | $66.06 | $26.4K | Yes (planned) | Form 4 ↗ |
| 2026-05-01 | 2026-05-01 | Sandler Laura Lee, Chief Operating Officer | SSale | −300.00 | $65.10 | $19.5K | Yes (planned) | Form 4 ↗ |
| 2026-05-01 | 2026-05-01 | Sandler Laura Lee, Chief Operating Officer | SSale | −1.80K | $64.15 | $115K | Yes (planned) | Form 4 ↗ |
| 2026-05-01 | 2026-05-01 | Sandler Laura Lee, Chief Operating Officer | SSale | −2.20K | $62.58 | $138K | Yes (planned) | Form 4 ↗ |
| 2026-05-01 | 2026-05-01 | Sandler Laura Lee, Chief Operating Officer | MExercise | +5.00K | $7.80 | $39.0K | Yes (planned) | Form 4 ↗ |
| 2026-04-15 | 2026-04-15 | Goncalves Joana Chief Medical Officer | SSale | −500.00 | $67.38 | $33.7K | Yes (planned) | Form 4 ↗ |
| 2026-04-15 | 2026-04-15 | Goncalves Joana, Chief Medical Officer | SSale | −2.27K | $66.56 | $151K | Yes (planned) | Form 4 ↗ |
| 2026-04-15 | 2026-04-15 | Goncalves Joana, Chief Medical Officer | SSale | −4.23K | $65.73 | $278K | Yes (planned) | Form 4 ↗ |
| 2026-04-15 | 2026-04-15 | Goncalves Joana, Chief Medical Officer | MExercise | +3.50K | $7.80 | $27.3K | Yes (planned) | Form 4 ↗ |
| 2026-04-15 | 2026-04-15 | Goncalves Joana, Chief Medical Officer | MExercise | +3.50K | $6.84 | $23.9K | Yes (planned) | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also ORKA’s full analysis or the market-wide insider trading feed. The tabs above jump to ORKA’s other SEC data.
Source: SEC Form 4 filings for ORKA, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.